drugset
drugset / Trial / NCT05203705

Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty

NCT05203705 ↗

Phase 2 Terminated 64 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a multi-center, randomized, open-label, double-blind, positive-controlled phase II clinical study evaluating the efficacy and safety of different doses of SHR2285 tablets vs. enoxaparin for the prevention of postoperative venous thromboembolism in patients undergoing elective unilateral total knee arthroplasty.

Timeline

Start
2022-03-07
Primary completion
2023-03-14
Completion
2023-03-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified — —
Subject SHR2285 Small molecule — —

Indications

No indication recorded.